v2.4.0.8
Acquisitions, Divestitures, Research Collaborations and License Agreements - Textual (Detail)
In Millions, except Per Share data, unless otherwise specified
 0 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended
Oct. 06, 2009
Mar. 31, 2011
Subsidiary
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2011
USD ($)
Dec. 31, 2013
Merck & Co., Inc [Member]
Apr. 30, 2013
Pfizer Inc [Member]
Dec. 31, 2013
Pfizer Inc [Member]
USD ($)
Dec. 31, 2013
Supera [Member]
USD ($)
Feb. 28, 2013
Supera [Member]
USD ($)
Dec. 31, 2013
AstraZeneca [Member]
USD ($)
Oct. 31, 2012
AiCuris [Member]
USD ($)
Oct. 31, 2012
AiCuris [Member]
EUR (€)
Apr. 30, 2012
Endocyte [Member]
USD ($)
May 31, 2011
Inspire Pharmaceuticals [Member]
USD ($)
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                              
Proceeds from collaborators                     $ 50        
Expenses for upfront and milestone payments made to collaborative partner               125       140 110 120  
Revenue and cost allocation percentage           60.00%   40.00%              
Length of time to give notice to terminate the agreement             12 months             90 days  
Controlling interest ownership of the joint venture, percentage                 51.00%            
Noncontrolling interest ownership of the joint venture, percentage                 49.00%            
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles                   89          
Business acquisition, assets acquired and liabilities assumed, IPR&D                   100          
Goodwill     12,301 12,134 12,155         103          
Business acquisition, assets acquired and liabilities assumed, deferred tax liabilities                   64          
Increase in noncontrolling interests                   112          
Increase in other paid-in-capital                   116          
In-process research and development impairment charges     279 200 587       15            
Potential future milestone payments                         332.5 880.0  
Amount of cash paid per share for acquisition                             $ 5.00
Purchase price for acquisition     246 0 373                   420
Number of subsidiaries sold   2                          
Length of time following closing of transaction committed to purchase certain development and manufacturing services at fair value   3 years                          
Gain on sale of manufacturing facilities and related assets         127                    
Extended marketing rights for both products (Remicade and Simponi) 15 years                            
Arbitration settlement payment         $ 500